NAME: Josef Smolen

POSITION: Editor-in-Chief, Annals of the Rheumatic Diseases

I have read and understood the BMJ’s policy on declaration of interests and declare the following:

In the past 5 years, I have received grants for my institution from: Abbvie, Astra-Zeneca, Janssen, Lilly, Novartis, Roche and Sanofi.

In the past 5 years I have received honoraria for consultations and/or speaking engagements from: Abbvie, Amgen, Astra-Zeneca, Astro, BMS, Celgene, Celltrion, Chugai, Genentech, Gilead, ILTOO, Janssen, Lilly, MSD, Novartis-Sandoz, Pfizer, Roche, Samsung, Sanofi, UCB.

I own no shares from pharmaceutical companies and have not filed any active patents.

I am a co-editor of the textbook Rheumatology for which the 8th Edition is currently prepared.

I have been a lead author, senior author or co-author on papers with numerous other authors. These include basic science papers as well as papers on outcomes research and scores and can all be seen on pubmed.

I have been a principal investigator or/and lead author of several clinical trials sponsored by industry which have all been published in peer reviewed journals.

I have been a convenor for various EULAR recommendations or other guidance documents, such as Treat-to-Target, which have all been published in (or will be submitted to) peer reviewed journals.

I have been a task force member for several EULAR or ACR/EULAR classification criteria and recommendations.

DATE: December 20, 2019